

## DAFTAR PUSTAKA

1. Ouassou H, Kharchoufa L, Bouhrim M, Daoudi NE, Imtara H, Bencheikh N, et al. The pathogenesis of coronavirus disease 2019 (COVID-19): Evaluation and Prevention. Vol. 2020, Journal of Immunology Research. Hindawi Limited; 2020.
2. Singhal T. A review of coronavirus disease-2019 (COVID-19). Vol. 87, Indian Journal of Pediatrics. Springer; 2020. p. 281–6.
3. World Health Organization, Global Situation [Internet]. [cited 2022 Nov 28]. Available from: <https://covid19.who.int/>
4. Hamid S, Mir MY, Rohela GK. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). Vol. 35, New Microbes and New Infections. Elsevier Ltd; 2020.
5. Cascella M, Rajnik M, Aleem A, et al. Features, evaluation, and treatment of coronavirus (COVID-19) [Updated 2022 Oct 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK554776>.
6. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. Available from: <https://doi.org/10.1007/s42399-020-00363-4>
7. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: Implications for understanding health and health services. *Ann Fam Med*. 2009;7(4):357–63.
8. Zulham Andi Ritonga., SKM. , M. (n.d.). *MODUL CETAK BAHAN AJAR EPIDEMIOLOGI* .
9. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. *Int J Antimicrob Agents*. 2020 May 1;55(5).
10. Hikmawati I, Setiyabudi R. Epidemiology of COVID-19 in Indonesia: common source and propagated source as a cause for outbreaks. *J Infect Dev Ctries*. 2021 May 1;15(5):646–52.

11. Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Vol. 508, Clinica Chimica Acta. Elsevier B.V.; 2020. P. 254–66.
12. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). JAMA. 2020 Aug 25;324(8):782.
13. Centers of Disease Control, COVID-19 Treatments and medications [Internet]. [cited 2022 Nov 28]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html>
14. Suryaputra GP, Apriningsih H, Wardani MM. Hubungan komorbid dengan mortalitas dan lama rawat inap pada pasien COVID-19 di rumah sakit UNS surakarta. Plexus Medical Journal. 2022 Februari.
15. Tanjung H, Julizar, Ermayanti S, Herman D, Mahata LE, Putra SP. Profil pasien COVID-19 dengan komorbid yang dirawat di RSUP Dr. M. Djamil Padang. JIKESI. 2023.
16. Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital based retrospective cohort study. Lancet Reg Heal - West Pacific. 2021;9:100108:1-9. doi: 10.1016/j.lanwpc.2021.100108.
17. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180(8):1081–9. doi: 10.1001/jamainternmed.2020.2033.